Summary
Microbiome is a Dutch R&D-performing SME developing molecular diagnostic assays based on human biomarkers with one of its focuses to celiac disease diagnostics. We developed a molecular diagnostic assay to screen HLA genotypes that are known to be associated with celiac disease (CD). Up to date, CD is diagnosed by serology (e.g. the presence of auto-antibodies to tissue transglutaminase 2 in the serum) and diagnosis requires further proof by analysis of a duodenal biopsy specimen. The collection of biopsy specimens requires an invasive examination and correct embedding of the tissue is essential for proper analysis of the tissue. This part of CD diagnosis is expensive, elaborate and prone to mistake. Innovation that trustworthy and efficiently can replace biopsy is in high demand. GRANROSE will enable Microbiome to strengthen its position as an innovative biotech SME, developing a novel assay, NeutroScan, for the CD market. GRANROSE will do this through hiring an Innovation Associate (IA).
• The IA will confirm and complete a biomarker panel that plays a role in gluten-related neutrophil function.
• The IA will develop an assay to study neutrophil function in gluten-related disease.
• The IA will perform a technical feasibility study for and investigate the market potential of the NeutroScan, an assay distinguishing gluten-related disease based on neutrophil function.
GRANROSE will not only bring major benefits for Microbiome, but is focused around the training of the Innovation Associate, thereby greatly improving his/her career development.
• Gaining novel technical skills and building an own research line with translational diagnostic applications.
• Gaining innovation and business management skills in a multidisciplinary setting.
• A training program tailored to his/her specific needs and major contribution to personal career development.
• The IA will confirm and complete a biomarker panel that plays a role in gluten-related neutrophil function.
• The IA will develop an assay to study neutrophil function in gluten-related disease.
• The IA will perform a technical feasibility study for and investigate the market potential of the NeutroScan, an assay distinguishing gluten-related disease based on neutrophil function.
GRANROSE will not only bring major benefits for Microbiome, but is focused around the training of the Innovation Associate, thereby greatly improving his/her career development.
• Gaining novel technical skills and building an own research line with translational diagnostic applications.
• Gaining innovation and business management skills in a multidisciplinary setting.
• A training program tailored to his/her specific needs and major contribution to personal career development.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/861910 |
| Start date: | 15-10-2019 |
| End date: | 14-10-2020 |
| Total budget - Public funding: | 130 062,50 Euro - 130 062,00 Euro |
Cordis data
Original description
Microbiome is a Dutch R&D-performing SME developing molecular diagnostic assays based on human biomarkers with one of its focuses to celiac disease diagnostics. We developed a molecular diagnostic assay to screen HLA genotypes that are known to be associated with celiac disease (CD). Up to date, CD is diagnosed by serology (e.g. the presence of auto-antibodies to tissue transglutaminase 2 in the serum) and diagnosis requires further proof by analysis of a duodenal biopsy specimen. The collection of biopsy specimens requires an invasive examination and correct embedding of the tissue is essential for proper analysis of the tissue. This part of CD diagnosis is expensive, elaborate and prone to mistake. Innovation that trustworthy and efficiently can replace biopsy is in high demand. GRANROSE will enable Microbiome to strengthen its position as an innovative biotech SME, developing a novel assay, NeutroScan, for the CD market. GRANROSE will do this through hiring an Innovation Associate (IA).• The IA will confirm and complete a biomarker panel that plays a role in gluten-related neutrophil function.
• The IA will develop an assay to study neutrophil function in gluten-related disease.
• The IA will perform a technical feasibility study for and investigate the market potential of the NeutroScan, an assay distinguishing gluten-related disease based on neutrophil function.
GRANROSE will not only bring major benefits for Microbiome, but is focused around the training of the Innovation Associate, thereby greatly improving his/her career development.
• Gaining novel technical skills and building an own research line with translational diagnostic applications.
• Gaining innovation and business management skills in a multidisciplinary setting.
• A training program tailored to his/her specific needs and major contribution to personal career development.
Status
CLOSEDCall topic
INNOSUP-02-2019-2020Update Date
27-10-2022
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
